Literature DB >> 20116281

Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals.

Ulrich Pecks1, Franka Seidenspinner, Claudia Röwer, Toralf Reimer, Werner Rath, Michael O Glocker.   

Abstract

A multifactorial differential analysis of serum proteins using mass spectrometry distinguished samples from pregnant women with severe early-onset preeclampsia (n = 11) from those of control individuals with uneventful pregnancies (n = 13). Serum proteins were fractionated by either their affinities to reversed-phase material coated magnetic beads or by fractionated precipitation. The on-average most abundant ion signals were observed at m/z 9390, 9103, and 8886. The best differentiating ion signals between the two sample groups were found at m/z 13,715, 13,834, and 13,891. The normalized intensities of these ion signals were on-average lower in the preeclampsia group than in the control group. The six ion signal intensities enabled sorting of the individual spectra with high accuracy. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed that a protein band migrating just above the 14 kDa marker band contained transthyretin (P02766; M(r) (avg.): 13,761). Densitometric analysis of the transthyretin bands showed lower intensities in the preeclampsia samples with respect to those of the controls. Nephelometric analysis of the serum samples determined the mean concentration of transthyretin in the preeclampsia group were lower (0.16 mg/mL; range: 0.13 to 0.20; SD: 0.03) than that in the control group (0.19 mg/mL; range: 0.14 to 0.22; SD: 0.02), substantiating the role of transthyretin concentration differences in the comparison of the two groups. Altogether, our findings support the theory of preeclampsia being a heterogeneous disorder that might be sub-classified by a defined proteome signature in maternal blood using multifactorial analysis of affinity-fractionated serum samples.
Copyright © 2010 American Society for Mass Spectrometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20116281     DOI: 10.1016/j.jasms.2009.12.013

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  53 in total

1.  [Analysis of a 1992 birth sample in Germany. 1: New percentile values of the body weight of newborn infants].

Authors:  M Voigt; K T Schneider; K Jährig
Journal:  Geburtshilfe Frauenheilkd       Date:  1996-10       Impact factor: 2.915

2.  Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia.

Authors:  Y M Lo; T N Leung; M S Tein; I L Sargent; J Zhang; T K Lau; C J Haines; C W Redman
Journal:  Clin Chem       Date:  1999-02       Impact factor: 8.327

3.  Effect of vitamin A status at the end of term pregnancy on the saturation of retinol binding protein with retinol.

Authors:  V Sapin; M C Alexandre; S Chaïb; J A Bournazeau; P Sauvant; P Borel; B Jacquetin; P Grolier; D Lémery; B Dastugue; V Azaïs-Braesco
Journal:  Am J Clin Nutr       Date:  2000-02       Impact factor: 7.045

4.  Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction.

Authors:  Irene Cetin; Veronica Cozzi; Fabio Pasqualini; Manuela Nebuloni; Cecilia Garlanda; Luca Vago; Giorgio Pardi; Alberto Mantovani
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Second-trimester maternal serum inhibin A concentration as an early marker for preeclampsia.

Authors:  J Aquilina; A Barnett; O Thompson; K Harrington
Journal:  Am J Obstet Gynecol       Date:  1999-07       Impact factor: 8.661

Review 7.  Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.

Authors:  Aravinthan Coomarasamy; Honest Honest; Spyros Papaioannou; Harry Gee; Khalid Saeed Khan
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

8.  Proteomic signature of human cancer cells.

Authors:  Masahiro Seike; Tadashi Kondo; Kazuyasu Fujii; Tesshi Yamada; Akihiko Gemma; Shoji Kudoh; Setsuo Hirohashi
Journal:  Proteomics       Date:  2004-09       Impact factor: 3.984

9.  Longitudinal determination of serum placental protein 13 during development of preeclampsia.

Authors:  Berthold Huppertz; Marei Sammar; Ilana Chefetz; Peruka Neumaier-Wagner; Clemens Bartz; Hamutal Meiri
Journal:  Fetal Diagn Ther       Date:  2008-08-28       Impact factor: 2.587

10.  A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound.

Authors:  K H Nicolaides; R Bindra; O M Turan; I Chefetz; M Sammar; H Meiri; J Tal; H S Cuckle
Journal:  Ultrasound Obstet Gynecol       Date:  2006-01       Impact factor: 7.299

View more
  9 in total

1.  Intact Transition Epitope Mapping - Targeted High-Energy Rupture of Extracted Epitopes (ITEM-THREE).

Authors:  Bright D Danquah; Claudia Röwer; KwabenaF M Opuni; Reham El-Kased; David Frommholz; Harald Illges; Cornelia Koy; Michael O Glocker
Journal:  Mol Cell Proteomics       Date:  2019-05-30       Impact factor: 5.911

2.  "De-novo" amino acid sequence elucidation of protein G'e by combined "top-down" and "bottom-up" mass spectrometry.

Authors:  Yelena Yefremova; Mahmoud Al-Majdoub; Kwabena F M Opuni; Cornelia Koy; Weidong Cui; Yuetian Yan; Michael L Gross; Michael O Glocker
Journal:  J Am Soc Mass Spectrom       Date:  2015-01-06       Impact factor: 3.109

3.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

4.  Human placental transthyretin in fetal growth restriction in combination with preeclampsia and the HELLP syndrome.

Authors:  Arrigo Fruscalzo; R Schmitz; W Klockenbusch; G Köhler; A P Londero; M Siwetz; B Huppertz
Journal:  Histochem Cell Biol       Date:  2012-07-31       Impact factor: 4.304

Review 5.  Mass spectrometry-based proteomics for pre-eclampsia and preterm birth.

Authors:  Kai P Law; Ting-Li Han; Chao Tong; Philip N Baker
Journal:  Int J Mol Sci       Date:  2015-05-14       Impact factor: 5.923

6.  MicroRNA regulation of Transthyretin in trophoblast differentiation and Intra-Uterine Growth Restriction.

Authors:  Sarbani Saha; Shreeta Chakraborty; Agnihotri Bhattacharya; Arati Biswas; Rupasri Ain
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

7.  Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics.

Authors:  Lina Youssef; Jezid Miranda; Miquel Blasco; Cristina Paules; Francesca Crovetto; Marta Palomo; Sergi Torramade-Moix; Héctor García-Calderó; Olga Tura-Ceide; Ana Paula Dantas; Virginia Hernandez-Gea; Pol Herrero; Nuria Canela; Josep Maria Campistol; Joan Carles Garcia-Pagan; Maribel Diaz-Ricart; Eduard Gratacos; Fatima Crispi
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

8.  Transthyretin as a novel candidate biomarker for preeclampsia.

Authors:  Lei Zhu; Yuxuan Chen; Chongdong Liu; Haiteng Deng; Nawei Zhang; Shengdian Wang; Zhenyu Zhang
Journal:  Exp Ther Med       Date:  2014-02-18       Impact factor: 2.447

9.  Precision Diagnostics by Affinity-Mass Spectrometry: A Novel Approach for Fetal Growth Restriction Screening During Pregnancy.

Authors:  Charles A Okai; Manuela Russ; Manja Wölter; Kristin Andresen; Werner Rath; Michael O Glocker; Ulrich Pecks
Journal:  J Clin Med       Date:  2020-05-07       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.